IL6 and neoplasm: Given the profound association of IL-6 with Th17 cells, recognized as significant contributors to inflammation in colitis or IBD, recent endeavors have sought to incorporate IL-6 blockade alongside dual PD-1 and CTLA-4 blockade to mitigate the irAE and enhance tumor immunity [299].